Clinical Trials Logo
  1. Home
  2. Carcinoma of Unknown Primary
  3. NCT00873119

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Carcinoma of Unknown Primary Clinical Trial

Official title:
An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary

Clinical Trial Summary

The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

Clinical Trial Description

This is an open-label, multinational, multicenter, randomized, comparative efficacy and safety study in previously untreated patients with carcinoma of unknown primary. Patients meeting inclusion and exclusion criteria will be randomized to treatment in Arm A (BelCaP) or Arm B (CaP). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00873119
Study type Interventional
Source Onxeo
Contact
Status Completed
Phase Phase 2
Start date February 2009
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003943 - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. Phase 2
Recruiting NCT02590055 - Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary Phase 2
Completed NCT00002507 - Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Phase 3
Recruiting NCT03740503 - Genomic Investigation of Unusual Responders
Terminated NCT00148135 - Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site Phase 2
Completed NCT00003582 - Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer Phase 1/Phase 2
Completed NCT00014456 - Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Completed NCT00357630 - Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary Phase 2
Active, not recruiting NCT01366144 - Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Completed NCT00004922 - Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Phase 2
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Withdrawn NCT00119314 - Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin Phase 2
Completed NCT00047125 - Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor Phase 3
Completed NCT00003657 - High-dose ICE With Amifostine Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting NCT02764216 - Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary Phase 2
Completed NCT00388024 - PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy N/A
Completed NCT00066781 - Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Phase 2